Edwards Lifesciences Corp (EW) Stake Lessened by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. cut its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 0.8% during the third quarter, HoldingsChannel.com reports. The firm owned 43,430 shares of the medical research company’s stock after selling 365 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Edwards Lifesciences were worth $7,561,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Voya Investment Management LLC raised its position in shares of Edwards Lifesciences by 47.9% during the second quarter. Voya Investment Management LLC now owns 911,238 shares of the medical research company’s stock worth $132,649,000 after purchasing an additional 295,113 shares during the period. Global X Management Co LLC grew its holdings in shares of Edwards Lifesciences by 13.4% during the second quarter. Global X Management Co LLC now owns 11,327 shares of the medical research company’s stock valued at $1,649,000 after buying an additional 1,342 shares in the last quarter. OppenheimerFunds Inc. grew its holdings in shares of Edwards Lifesciences by 5.7% during the second quarter. OppenheimerFunds Inc. now owns 161,270 shares of the medical research company’s stock valued at $23,476,000 after buying an additional 8,684 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Edwards Lifesciences by 3.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 794,667 shares of the medical research company’s stock valued at $115,680,000 after buying an additional 26,346 shares in the last quarter. Finally, Highstreet Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 14.3% during the second quarter. Highstreet Asset Management Inc. now owns 5,959 shares of the medical research company’s stock valued at $867,000 after buying an additional 744 shares in the last quarter. 82.55% of the stock is currently owned by institutional investors.

Shares of NYSE EW opened at $157.21 on Friday. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a one year low of $110.68 and a one year high of $175.00. The stock has a market capitalization of $34.14 billion, a price-to-earnings ratio of 41.37, a PEG ratio of 2.15 and a beta of 0.90.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The firm had revenue of $906.60 million for the quarter, compared to the consensus estimate of $927.56 million. During the same quarter in the previous year, the company posted $0.84 earnings per share. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.

In other Edwards Lifesciences news, Director Schack Wesley W. Von sold 1,319 shares of the business’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $160.96, for a total value of $212,306.24. Following the transaction, the director now owns 2,134 shares in the company, valued at $343,488.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Monday, October 29th. The shares were sold at an average price of $140.74, for a total value of $4,630,346.00. The disclosure for this sale can be found here. Insiders sold 187,156 shares of company stock worth $27,603,513 in the last 90 days. Corporate insiders own 1.84% of the company’s stock.

A number of brokerages have recently weighed in on EW. Morgan Stanley lifted their price target on Edwards Lifesciences from $157.00 to $180.00 and gave the company an “overweight” rating in a report on Friday. Zacks Investment Research downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, October 25th. Barclays set a $143.00 price target on Edwards Lifesciences and gave the company a “sell” rating in a report on Wednesday, October 24th. Raymond James lifted their price target on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Cowen set a $190.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Friday, November 30th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $162.85.

WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2018/12/08/edwards-lifesciences-corp-ew-stake-lessened-by-tocqueville-asset-management-l-p.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: What is a Futures Contract?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit